Comparison of clinical effects of two latanoprost 0.005% solutions (Xalatan® and Arulatan®) in primary open-angle glaucoma or ocular hypertensive patients: a randomized clinical trial

Código QR

Comparison of clinical effects of two latanoprost 0.005% solutions (Xalatan® and Arulatan®) in primary open-angle glaucoma or ocular hypertensive patients: a randomized clinical trial

Rodrigo A Brant Fernandes,1 Luci Meire P Silva,1 Diego Torres Dias,1 Rafael Henrique Pereira,2 Rubens Belfort Jr,1,2 Tiago Santos Prata1–31Department of Ophthalmology and Visual Sciences, Federal University of São Paulo, São Paulo, SP, Brazil; 2IPEPO/Vision Institute...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Brant Fernandes RA, Silva LMP, Dias DT, Pereira RH, Belfort Jr R, Prata TS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	glaucoma latanoprost intraocular pressure reduction Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/958c2adb33bb4fd4a59ec68033d14af2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Improved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism
por: Radcliffe N, et al.
Publicado: (2020)

Intraocular pressure and visual field changes in normal-tension glaucoma patients treated using either unoprostone or latanoprost: a prospective comparative study
por: Takemoto D, et al.
Publicado: (2017)

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction
por: Beck DER, et al.
Publicado: (2017)

The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study
por: Okumichi H, et al.
Publicado: (2017)

Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma
por: Ikeda Y, et al.
Publicado: (2016)

Clinical Evaluation of a Novel Electromechanical Topical Ocular Drug Delivery System: Two Phase 1 Proof of Concept Studies
por: Quiroz-Mercado H, et al.
Publicado: (2020)

Physiochemical Properties and Cytotoxicity of a Benzalkonium Chloride-Free, Micellar Emulsion Ophthalmic Formulation of Latanoprost
por: Halder A, et al.
Publicado: (2020)

Icare® rebound tonometers: review of their characteristics and ease of use
por: Nakakura S
Publicado: (2018)

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy
por: Inoue K, et al.
Publicado: (2012)

Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study
por: Economou MA, et al.
Publicado: (2018)

Short-Term Efficacy and Safety of Switching from a Latanoprost/Timolol Fixed Combination to a Latanoprost/Carteolol Fixed Combination
por: Inoue K, et al.
Publicado: (2020)

Comparison of successful outcome predictors for MicroPulse® laser trabeculoplasty and selective laser trabeculoplasty at 6 months
por: Hirabayashi MT, et al.
Publicado: (2019)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
por: Kanamoto T, et al.
Publicado: (2012)

Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost
por: Erb C, et al.
Publicado: (2021)

Comparative Study between Topical Latanoprost versus Topical 5- Fluorouracil after Dermabrasion for Treatment of Non-Segmental Stable Vitiligo
por: Rehab Abd El Razek, et al.
Publicado: (2021)

Goldmann tonometer error correcting prism: clinical evaluation
por: McCafferty S, et al.
Publicado: (2017)

Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose
por: Pasquale LR, et al.
Publicado: (2018)

Phacoemulsification: an alternative for prophylaxis of a glaucomatous crisis
por: Stock RA, et al.
Publicado: (2019)

Intraocular pressure dynamics with prostaglandin analogs: a clinical application of water-drinking test
por: Özyol P, et al.
Publicado: (2016)

Self-monitoring of intraocular pressure using Icare HOME tonometry in clinical practice
por: Cvenkel B, et al.
Publicado: (2019)

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
por: Michael J Miyashiro, et al.
Publicado: (2010)

Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials
por: Uusitalo H, et al.
Publicado: (2016)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
por: Shen J, et al.
Publicado: (2017)

Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg
por: Yelda Buyru &Ouml;zkurt, et al.
Publicado: (2009)

Viscodilation of Schlemm’s canal for the reduction of IOP via an ab-interno approach
por: Gallardo MJ, et al.
Publicado: (2018)

MicroPulse® Transscleral Laser Therapy – Fluence May Explain Variability in Clinical Outcomes: A Literature Review and Analysis
por: Grippo TM, et al.
Publicado: (2021)

Combined iStent® Inject Trabecular Micro-Bypass and Phacoemulsification in Australian Patients with Open-Angle Glaucoma
por: Salby AM, et al.
Publicado: (2020)

Mid-Term Evaluation of iStent Inject® Trabecular Micro-Bypass Stent Implantation with or without Phacoemulsification: A Retrospective Study
por: Silveira Seixas RC, et al.
Publicado: (2020)

Efficacy and Safety of VisuEvo® and Cationorm® for the Treatment of Evaporative and Non-Evaporative Dry Eye Disease: A Multicenter, Double-Blind, Cross-Over, Randomized Clinical Trial
por: Fogagnolo P, et al.
Publicado: (2020)

Efficacy and safety of switching to latanoprost 0.005%–timolol maleate 0.5% fixed-combination eyedrops from an unfixed combination for 36 months
por: Inoue K, et al.
Publicado: (2014)

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
por: David A Godfrey, et al.
Publicado: (2009)

Outcome Of MicroPulse® Transscleral Photocoagulation In Different Types Of Glaucoma
por: Al Habash A, et al.
Publicado: (2019)

The Baerveldt Glaucoma Drainage Device: Efficacy, Safety, and Place in Therapy
por: Poelman HJ, et al.
Publicado: (2020)

Factors influencing the filtration-bleb volume after Ex-PRESS® surgery
por: Tojo N, et al.
Publicado: (2018)

A Comparative Study Between the Goldmann Applanation Tonometer and the Non-Contact Air-Puff Tonometer (Huvitz HNT 7000) in Normal Eyes
por: Stock RA, et al.
Publicado: (2021)

Astigmatism management in cataract surgery with Precizon® toric intraocular lens: a prospective study
por: Vale C, et al.
Publicado: (2016)

Visian® ICLV4c™ and Artiflex®: Comparative Analysis with the HD Analyser™ and Integration with Subjective Performance and Anatomical Parameters
por: Baptista PM, et al.
Publicado: (2020)

A multicenter retrospective comparison of goniotomy versus trabecular bypass device implantation in glaucoma patients undergoing cataract extraction
por: Dorairaj SK, et al.
Publicado: (2018)

Outcome of phacoemulsification combined with excisional goniotomy using the Kahook Dual Blade in severe glaucoma patients at 6 months
por: Hirabayashi MT, et al.
Publicado: (2019)

Circumferential viscodilation of Schlemm’s canal for open-angle glaucoma: ab-interno vs ab-externo canaloplasty with tensioning suture
por: Gallardo MJ, et al.
Publicado: (2018)